Safe-line-tech: The Safe-line Technique as Additional Attempt to Mitigate Spinal Cord Ischemia After Endovascular Exclusion of TAAA

Sponsor
University Hospital Padova (Other)
Overall Status
Recruiting
CT.gov ID
NCT05758844
Collaborator
(none)
100
1
43.1
2.3

Study Details

Study Description

Brief Summary

To assess safety and feasebility of the "safe-line" technique in a multicenter international collaboration.

Condition or Disease Intervention/Treatment Phase
  • Procedure: safe-line technique

Detailed Description

To assess safety and efficacy of a technique for temporary aneurysm sac re-perfusion (TASreP) after total endovascular exclusion of TAAA, using a guide-wire left into the aneurysm sac. The technique can be applied both in elective that urgent cases.

The guide-wire aim to be a "safe-line" for fast temporary trans-sealing aneurysm sac re-perfusion in case of SCI occurring in the early post-operative period (48-to 72h).

Before completing exclusion, from the percutaneous femoral access, a second buddy-wire (V-18 guidewire; Boston Scientific) is advanced and left posterior to the endograft into the aneurysmal sac; through the main guide-wire, the final aneurysm exclusion is completed with distal stent-graft deployment and the femoral access sealed with Proglide leaving in place the sole V.018 draped in a sterile fashion. In the case of SCI occurrence in the post-operative period up to 48-72 hrs, the trans-sealing V.18 "safe-line" can be rapidly exchanged with a 6F/65 cm long Destination cm guiding sheath (Terumo) and positioned into the aneurysmal sac; this can be connected to a 6F introducer from the contralateral femoral artery and the sac perfused in a retrograde fashion.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
100 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
The Safe-line Technique as Additional Attempt to Mitigate Spinal Cord Ischemia After Endovascular Thoraco-abdominal Aneurysm Repair
Anticipated Study Start Date :
Apr 30, 2023
Anticipated Primary Completion Date :
Dec 1, 2025
Anticipated Study Completion Date :
Dec 1, 2026

Outcome Measures

Primary Outcome Measures

  1. Incidence of adverse events [7 days]

    collect eventual complications (incidence of: 1- axis thrombosis; 2- microembolization; 3-hematoma)

  2. Incidence of spinal cord ischemia improvement or resolution [30 days]

    collect all events that in case of post-operative (48-72hrs) spinal cord ischemia had symptoms mitigation (1-paraplegia improvement; 2 - paraplegia complete resolution)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Thoraco-abdominal aortic aneurysm including type I,II,III,IV and V.

  • Pararenale aneurysm

  • Thoracoabdominal aortic aneurysm Elective and Urgent, endovascular repair;

  • Endovascular repair of any thoracoabdominal aortic condition

Exclusion Criteria:

-thoraco-abdominal aortic aneurysm open repair

Contacts and Locations

Locations

Site City State Country Postal Code
1 Vascular and Endovascular Clinic - Padova University Padova Italy 35020

Sponsors and Collaborators

  • University Hospital Padova

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Michele Piazza, Associate Professor, University Hospital Padova
ClinicalTrials.gov Identifier:
NCT05758844
Other Study ID Numbers:
  • Safe-line.1
First Posted:
Mar 8, 2023
Last Update Posted:
Mar 8, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 8, 2023